Distal extremities soft tissue sarcomas: Are they so different from other limb localizations?


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 07 10 2018
accepted: 16 12 2018
pubmed: 5 1 2019
medline: 2 3 2019
entrez: 5 1 2019
Statut: ppublish

Résumé

Soft tissue sarcoma localization in distal extremities (DESTS) of the limbs (hand/fingers, and foot/toes) is unusual. The literature is scarce about their behavior and this study was designed to assess their epidemiological characteristics, outcomes, and prognosis compared to other limb localizations (OLSTS). From 1980 to 2010, adult DESTS and OLSTS in 22 centers were included. Demographics, tumor type, treatment modalities, and latest follow-up status were collected. Primary endpoints were overall survival and local/metastatic recurrence incidences. Two hundred five DESTS and 3001 OLSTS were included. The patients were younger, with more female and smaller tumors in DESTS. There were more clear cell/epithelioid sarcomas, synovial sarcomas, and myxoid liposarcomas vs more dedifferentiated liposarcomas in OLSTS. DESTS tumors were less irradiated and more often amputated (24.3% vs 3.4%). The five-year survival rate was 78.2% compared to 68.6% in OLSTS and after multivariate analysis, STS localization did not impact survival or local/metastatic recurrence. Though rare and smaller than other limb localizations, DESTS are to be considered as aggressive. Despite a higher amputation rate, the prognosis remains the same as in OLSTS. Limb sparing vs amputation should be carefully assessed in DESTS, especially if grade 3 or of a poor prognosis histological subtype.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Soft tissue sarcoma localization in distal extremities (DESTS) of the limbs (hand/fingers, and foot/toes) is unusual. The literature is scarce about their behavior and this study was designed to assess their epidemiological characteristics, outcomes, and prognosis compared to other limb localizations (OLSTS).
METHODS METHODS
From 1980 to 2010, adult DESTS and OLSTS in 22 centers were included. Demographics, tumor type, treatment modalities, and latest follow-up status were collected. Primary endpoints were overall survival and local/metastatic recurrence incidences.
RESULTS RESULTS
Two hundred five DESTS and 3001 OLSTS were included. The patients were younger, with more female and smaller tumors in DESTS. There were more clear cell/epithelioid sarcomas, synovial sarcomas, and myxoid liposarcomas vs more dedifferentiated liposarcomas in OLSTS. DESTS tumors were less irradiated and more often amputated (24.3% vs 3.4%). The five-year survival rate was 78.2% compared to 68.6% in OLSTS and after multivariate analysis, STS localization did not impact survival or local/metastatic recurrence.
CONCLUSION CONCLUSIONS
Though rare and smaller than other limb localizations, DESTS are to be considered as aggressive. Despite a higher amputation rate, the prognosis remains the same as in OLSTS. Limb sparing vs amputation should be carefully assessed in DESTS, especially if grade 3 or of a poor prognosis histological subtype.

Identifiants

pubmed: 30609044
doi: 10.1002/jso.25359
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-488

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Jean-Camille Mattei (JC)

Assistance Publique des Hôpitaux de Marseille, Hôpital Nord, Départment de Chirurgie Orthopédique des Prs. Curvale et Rochwerger, Marseille, France.
Faculté de Médecine de la Timone, Génétique Médicale et génomique fonctionnelle, UMR S910 Inserm, Université Aix-Marseille 2, Marseille, France.

Véronique Brouste (V)

Institut Bergonie, INSERM U 897, Département Biostatistique, ISPED, Université Victor Segalen Bordeaux 2, Case 11, Bordeaux, France.

Philippe Terrier (P)

Département de Biologie et de Pathologie Médicales, Institut de Cancérologie Gustave-Roussy, Villejuif, France.

Sylvie Bonvalot (S)

Institut Curie, Département de Chirurgie 8, PSL Research University, Paris, France.

Axel Lecesne (A)

Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Eberhard Stoeckle (E)

Department of Surgery, Institut Bergonié, Regional Cancer Centre, Bordeaux, France.

Antoine Italiano (A)

Departement d'oncologie Medicale, CLCC Institut Bergonie, Bordeaux, France.

Dominique Ranchere-Vince (D)

Department of Pathology, Leon Berard Center, Lyon, France.

Pierre Meeus (P)

Department of Surgery, Centre Leon Berard, University Lyon 1, Lyon, France.

Marick Laé (M)

Service de Pathologie, Institut Curie, Paris Sciences Lettres Research University, Département de Médecine Diagnostique et Théranostique, Paris, France.
Service de Pathologie, Centre Henri Becquerel, INSERM U1245, UNIROUEN, Normandie Université, rue d'Amiens, Rouen, France.

Philippe Rosset (P)

Département Chirurgie Orthopédique et Traumatologique 2, Hôpital Trousseau, Université François-Rabelais de Tours, CHU de Tours, Tours, France.

Alexandre Rochwerger (A)

Assistance Publique des Hôpitaux de Marseille, Hôpital Nord, Départment de Chirurgie Orthopédique des Prs. Curvale et Rochwerger, Marseille, France.
Faculté de Médecine de la Timone, Génétique Médicale et génomique fonctionnelle, UMR S910 Inserm, Université Aix-Marseille 2, Marseille, France.

Jean Michel Coindre (JM)

Département d'anatomo-pathologie de l'Institut Bergonié.

Sébastien Salas (S)

Faculté de Médecine de la Timone, Génétique Médicale et génomique fonctionnelle, UMR S910 Inserm, Université Aix-Marseille 2, Marseille, France.
Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH